GCM
LFCR icon

Graham Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Graham Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,580
Closed -$111K – 1362
2025
Q4 		$111K Buy
+13,580
New +$100K ﹤0.01% 1130

Other funds holding LFCR

2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GC
Grizzlyrock Capital Chicago, Illinois $143M AUM 6.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Graham Capital Management's LFCR Position: Q1 2026 in Review

Graham Capital Management sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 13,580 shares — an estimated $111K sold.

Graham Capital Management first reported a position in LFCR in Q4 2025 and held it in 1 quarter. The position peaked at $111K in Q4 2025. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • Graham Capital Management reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 13,580 Lifecore Biomedical shares in Q1 2026, an estimated $111K.
  • Graham Capital Management first reported a position in Lifecore Biomedical in Q4 2025 and held it in 1 quarter.
  • Graham Capital Management's Lifecore Biomedical position peaked at $111K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.